<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00642187</url>
  </required_header>
  <id_info>
    <org_study_id>SD-004-0620</org_study_id>
    <secondary_id>D5254C00620</secondary_id>
    <nct_id>NCT00642187</nct_id>
  </id_info>
  <brief_title>New Version Pulmicort Turbuhaler USA Adults</brief_title>
  <official_title>A Placebo-controlled Comparison of the Efficacy and Safety of the Current US Version of Pulmicort (Budesonide) Turbuhaler and the New Version of Pulmicort Turbuhaler in Asthmatic Adults Currently Treated With Inhaled Steroids.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A comparison of the safety, efficacy and budesonide pharmacokinetics of the currently&#xD;
      approved Pulmicort Turbuhaler with a new version of the inhaler, in adult patients who have&#xD;
      asthma and are currently being treated with inhaled steroids. In addition the study evaluated&#xD;
      the functionality of the new inhaler at the end of its intended life.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2002</start_date>
  <completion_date type="Actual">October 2004</completion_date>
  <primary_completion_date type="Actual">October 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Forced Expiratory Volume in 1 second</measure>
    <time_frame>Week 2, 4 and 8, then at week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Forced Vital Capacity, Morning Peak Expiratory Flow, Daytime and nighttime asthma symptom scores, beta-agonist use and discontinuation rate.</measure>
    <time_frame>Week 2, 4 and 8, then at week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>Week 2,4 and 8, then at week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of budesonide (AUC, maximum concentration and time to maximum concentration)</measure>
    <time_frame>6 or 12 hours post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">525</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pulmicort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>budesonide</intervention_name>
    <arm_group_label>1</arm_group_label>
    <other_name>Pulmicort</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females at least 18 years old with a diagnosis of asthma (as defined by the&#xD;
             ATS) for at least 6 months.&#xD;
&#xD;
          -  To enter the run in period, subjects were also required to have the following:&#xD;
&#xD;
          -  A forced expiratory volume (FEV1) in 1 second of 60% to 90% of predicted normal,&#xD;
             airway reversibility of at least 12% and 0.20 L, use of orally inhaled corticosteroids&#xD;
             for at least 3 months prior to the study.&#xD;
&#xD;
          -  At Visit 2, subjects who met additional entry criteria related to rescue medication&#xD;
             use and asthma symptom scores during the run in period plus visit specific FEV1&#xD;
             requirements were assigned to randomized treatments&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Life threatening asthma, Two or more overnight hospitalisations for asthma within 1&#xD;
             year or any emergency room visit for asthma within 6 months of starting study.&#xD;
&#xD;
          -  Use of steroid tablets or injections during the month (28 days) prior to Visit 1 and&#xD;
             use of other asthma medicines (except rescue medication) within 2 weeks prior to the&#xD;
             study.&#xD;
&#xD;
          -  Any acute exacerbation of asthma or a respiratory tract infection within 30 days prior&#xD;
             to the study. Subject must not smoke or have smoked within 6 months of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bertil Andersson</last_name>
    <role>Study Director</role>
    <affiliation>AZ employee</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lars-Göran Carlsson</last_name>
    <role>Study Director</role>
    <affiliation>AZ employee</affiliation>
  </overall_official>
  <verification_date>January 2011</verification_date>
  <study_first_submitted>March 18, 2008</study_first_submitted>
  <study_first_submitted_qc>March 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2008</study_first_posted>
  <last_update_submitted>January 21, 2011</last_update_submitted>
  <last_update_submitted_qc>January 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2011</last_update_posted>
  <responsible_party>
    <name_title>Lars-Göran Carlsson</name_title>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Pulmicort</keyword>
  <keyword>Turbuhaler</keyword>
  <keyword>Budesonide</keyword>
  <keyword>Flexhaler</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

